Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment.
about
Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutionsQualitative immune modulation by interleukin-2 (IL-2) adjuvant therapy in immunological non responder HIV-infected patients.Interleukin-2 as an adjunct to antiretroviral therapy for HIV-positive adults.IL-2 immunotherapy to recently HIV-1 infected adults maintains the numbers of IL-17 expressing CD4+ T (T(H)17) cells in the periphery.Immune interventions in HIV infection.Factors associated with poor immunologic response to virologic suppression by highly active antiretroviral therapy in HIV-infected womenCytokine therapies in HIV-1 infection: present and future.Partial immune reconstitution following highly active antiretroviral therapy: can adjuvant interleukin-2 fill the gap?The use of interleukin-2 in human immunodeficiency virus infection.Antiretroviral therapy in advanced HIV-1 infection.The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options.Functions of γC cytokines in immune homeostasis: current and potential clinical applications.Immunotherapeutic restoration in HIV-infected individuals.Immunodiscordant responses to HAART--mechanisms and consequences.Discordant responses to cART in HIV-1 patients in the era of high potency antiretroviral drugs: clinical evaluation, classification, management prospects.Enhancement of specific cellular immune response induced by DNA vaccines encoding PML-RARalpha and hIL-2 genes.Safety and efficacy of treatment using interleukin-2 in a patient with idiopathic CD4(+) lymphopenia and Mycobacterium avium-intracellulare.
P2860
Q27021524-FF29D811-E33B-44D6-9122-53C34AD54667Q33760657-D7876FA9-C749-4507-B238-F780CE5F6B86Q33761480-8A7D9631-7201-4C87-B0AC-8B0FAE9E0777Q34112781-9FF9FBE4-EDB1-4C16-A675-FB98A2BAF1F2Q34351326-A2671184-15E9-4F96-905A-A946DBA1ABA4Q35077997-0A2ADF52-842D-4079-B78C-982FE856136FQ35917144-D9C8342C-8B84-4D28-9FA4-B2BF3B92CD4AQ36054268-7618858A-4B27-46E4-B7BE-B83797CD1D5CQ36070906-24D4A705-CF57-4E70-8F57-984A5A1AFAD1Q36120482-13AB2B10-0A5E-45B9-843E-D2FDD3669079Q37362435-25A7BB0E-D427-4E7A-A393-D37B1858DF76Q37475949-9EE5EF50-B9EA-4578-8E21-A87C111176C8Q37842335-C0BF4474-28C5-42C6-B75E-500F2A1E56F8Q38156230-838A6575-EA4C-447C-AB81-80F39B57D9A9Q38619193-7943A1CD-4316-46FF-91A9-A068587B9F2FQ39710209-8EA0B330-E517-4490-8E47-F04A0323667AQ42170591-96A5DC66-062A-48C2-B161-83BF1BC7B730
P2860
Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Low-dose prolonged intermitten ...... th advanced immune impairment.
@en
Low-dose prolonged intermitten ...... th advanced immune impairment.
@nl
type
label
Low-dose prolonged intermitten ...... th advanced immune impairment.
@en
Low-dose prolonged intermitten ...... th advanced immune impairment.
@nl
prefLabel
Low-dose prolonged intermitten ...... th advanced immune impairment.
@en
Low-dose prolonged intermitten ...... th advanced immune impairment.
@nl
P2093
P50
P356
P1476
Low-dose prolonged intermitten ...... ith advanced immune impairment
@en
P2093
Chiara Molteni
Daniele Manganaro
Fabio Franzetti
Luca Meroni
Mauro Moroni
Sabrina Fossati
Velislava Terzieva
P304
P356
10.1086/342479
P407
P50
P577
2002-08-09T00:00:00Z